Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice
Léa Gherardi,* Lucie Aubergeon,* Mélanie Sayah, Jean-Daniel Fauny, Hélène Dumortier, Fanny Monneaux CNRS UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, 67084, France*These authors contributed equally to...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/targeting-b-and-t-lymphocyte-attenuator-regulates-lupus-disease-develo-peer-reviewed-fulltext-article-ITT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594310814498816 |
|---|---|
| author | Gherardi L Aubergeon L Sayah M Fauny JD Dumortier H Monneaux F |
| author_facet | Gherardi L Aubergeon L Sayah M Fauny JD Dumortier H Monneaux F |
| author_sort | Gherardi L |
| collection | DOAJ |
| description | Léa Gherardi,* Lucie Aubergeon,* Mélanie Sayah, Jean-Daniel Fauny, Hélène Dumortier, Fanny Monneaux CNRS UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, 67084, France*These authors contributed equally to this workCorrespondence: Fanny Monneaux, CNRS UPR3572, Institut de Biologie Moléculaire et Cellulaire, 2 Allée Konrad Roentgen, Strasbourg, 67084, France, Email f.monneaux@ibmc-cnrs.unistra.frPurpose: The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4+ T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.Methods: BTLA expression and function were analyzed in young (10– 12-week-old) and old-diseased NZB/W mice (> 35-week-old with proteinuria) in comparison to age-related BALB/W control mice. 20– 22 weeks old NZB/W mice (n=10) were injected i.p with 3 mg/kg, twice a week for ten weeks, with the anti-BTLA antibody 6F7 or its isotype control.Results: In old-diseased NZB/W mice, BTLA expression is slightly modified in B cell subsets whereas CD4+ T cells display impaired BTLA functionality. Administration of the 6F7 anti-BTLA antibody into 20– 22 week-old NZB/W mice resulted in a delayed onset of proteinuria (p< 0.01), limited kidney damages (p< 0.05) and an increased survival rate (p< 0.01) compared to isotype-treated mice. This beneficial effect was associated with a decrease in circulating B cell and spleen follicular B cell numbers. Regarding its mode of action, we demonstrated that the 6F7 antibody is not a depleting antibody and does not block HVEM binding to BTLA, but instead induces BTLA down modulation and exhibits in vivo agonist activity.Conclusion: Overall, our data confirm the involvement of BTLA in lupus pathogenesis and provide the first evidence that BTLA is a potential therapeutic target for the treatment of lupus.Keywords: systemic lupus erythematosus, BTLA, lupus mice, inhibitory receptors |
| format | Article |
| id | doaj-art-f0666143c2944624bd31067f66675603 |
| institution | Kabale University |
| issn | 2253-1556 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj-art-f0666143c2944624bd31067f666756032025-01-19T16:42:59ZengDove Medical PressImmunoTargets and Therapy2253-15562025-01-01Volume 1472399333Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W MiceGherardi LAubergeon LSayah MFauny JDDumortier HMonneaux FLéa Gherardi,* Lucie Aubergeon,* Mélanie Sayah, Jean-Daniel Fauny, Hélène Dumortier, Fanny Monneaux CNRS UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, Institute of Molecular and Cellular Biology, Strasbourg, 67084, France*These authors contributed equally to this workCorrespondence: Fanny Monneaux, CNRS UPR3572, Institut de Biologie Moléculaire et Cellulaire, 2 Allée Konrad Roentgen, Strasbourg, 67084, France, Email f.monneaux@ibmc-cnrs.unistra.frPurpose: The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4+ T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.Methods: BTLA expression and function were analyzed in young (10– 12-week-old) and old-diseased NZB/W mice (> 35-week-old with proteinuria) in comparison to age-related BALB/W control mice. 20– 22 weeks old NZB/W mice (n=10) were injected i.p with 3 mg/kg, twice a week for ten weeks, with the anti-BTLA antibody 6F7 or its isotype control.Results: In old-diseased NZB/W mice, BTLA expression is slightly modified in B cell subsets whereas CD4+ T cells display impaired BTLA functionality. Administration of the 6F7 anti-BTLA antibody into 20– 22 week-old NZB/W mice resulted in a delayed onset of proteinuria (p< 0.01), limited kidney damages (p< 0.05) and an increased survival rate (p< 0.01) compared to isotype-treated mice. This beneficial effect was associated with a decrease in circulating B cell and spleen follicular B cell numbers. Regarding its mode of action, we demonstrated that the 6F7 antibody is not a depleting antibody and does not block HVEM binding to BTLA, but instead induces BTLA down modulation and exhibits in vivo agonist activity.Conclusion: Overall, our data confirm the involvement of BTLA in lupus pathogenesis and provide the first evidence that BTLA is a potential therapeutic target for the treatment of lupus.Keywords: systemic lupus erythematosus, BTLA, lupus mice, inhibitory receptorshttps://www.dovepress.com/targeting-b-and-t-lymphocyte-attenuator-regulates-lupus-disease-develo-peer-reviewed-fulltext-article-ITTsystemic lupus erythematosusbtlalupus miceinhibitory receptors |
| spellingShingle | Gherardi L Aubergeon L Sayah M Fauny JD Dumortier H Monneaux F Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice ImmunoTargets and Therapy systemic lupus erythematosus btla lupus mice inhibitory receptors |
| title | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice |
| title_full | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice |
| title_fullStr | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice |
| title_full_unstemmed | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice |
| title_short | Targeting B and T Lymphocyte Attenuator Regulates Lupus Disease Development in NZB/W Mice |
| title_sort | targeting b and t lymphocyte attenuator regulates lupus disease development in nzb w mice |
| topic | systemic lupus erythematosus btla lupus mice inhibitory receptors |
| url | https://www.dovepress.com/targeting-b-and-t-lymphocyte-attenuator-regulates-lupus-disease-develo-peer-reviewed-fulltext-article-ITT |
| work_keys_str_mv | AT gherardil targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice AT aubergeonl targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice AT sayahm targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice AT faunyjd targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice AT dumortierh targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice AT monneauxf targetingbandtlymphocyteattenuatorregulateslupusdiseasedevelopmentinnzbwmice |